News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020

Photon IMRT Treatment Group Displays No Significant Survival Difference Between Arms

NRG-BN001 photon IMRT treatment group displays no significant survival difference between arms for patients with glioblastoma, proton treatment group still accruing

Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

October 27, 2020 — A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM). Although there were no differences between arms, results suggest that MGMT methylation and RPA are predictive of progression-free survival (PFS). The proton therapy treatment group 2 of this trial is ongoing. The preliminary results were presented at the virtual edition of the American Society for Radiation Oncology's (ASTRO) Annual Meeting in October 2020.

NRG-BN001 enrolled 229 eligible patients to be randomly assigned to receive either SD-RT or DI-IMRT. Patients were also stratified by RPA class and MGMT methylation status. Of the 229 trial participants, 58% were MGMT unmethylated and 75% were RPA class IV. Researchers were primarily studying OS rates between the two treatments; however, secondary objectives of the trial were to track PFS, treatment-related toxicity between arms, patient-reported symptom burden, and change to neurocognitive function.

Results demonstrated no significant difference in grade 3 or greater toxicity between the SD-RT and DI-IMRT treatments. The median OS rate for DI-IMRT was 18.7 months (95% CI: 16.0, 23.5) and 16.3 months for the SD-RT arm (95% CI: 13.9, 19.8). At 30 months, 30.4% of the patients on the DI-IMRT arm (95% CI: 21.8, 39.1) and 21.6% of the patients on the SD-RT arm (95% CI: 12.7, 30.6) were still living. Median PFS also exhibited no difference (HR=1.23, 95% CI: 0.93, 1.64, p=0.18).

While there was no difference in median OS between treatment arms, median OS was significantly shorter for MGMT unmethylated GBM (15.1 months, 95% CI: 13.9, 17.8) when compared to MGMT methylated GBM (28.3 months, 95% CI: 21.5, 38.3, p<0.001). Additionally, median OS was also shorter for RPA class V (10.8 months, 95% CI 4.9-14.9) when compared to RPA class III (20.5 months, 15.5, 29.8) or IV (18.5 mo, 15.7, 21.5) (p=0.02). Researchers also observed a shorter median PFS in the MGMT methylated cohort after DI-IMRT treatment (8.8 months, 95% CI 6.0, 11.1) when compared to the SD-RT treatment (14.1 months, 95%CI 8.2, 27.7, p=0.04).

"Although this first group of IMRT dose-intensification did not cross significance threshold for further testing in a phase III trial, it is important to note the predictive implications of MGMT methylation and RPA class with regards to progression-free and overall survival. Future research of treatment intensification should continue to account for these factors in this disease," stated Vinai Gondi, M.D., the director of research at the Northwestern Medicine Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

The second group of this trial will be surveying DI-RT with proton therapy in place of IMRT. This group continues to accrue patients, and results will be announced at a future time.

"We look forward to the results that come from this study's second group involving dose-intensification using proton therapy. Proton therapy is hypothesized to further improve survival by preventing radiotherapy-related circulating lymphopenia, which has been shown to impact survival in this patient population," Gondi added.

For more information: www.nrgoncology.org

Related Content

The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...